There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Nurix Therapeutics (NRIX – Research Report), Ascendis Pharma (ASND – Research Report) and Lantheus (LNTH – Research Report) with bullish sentiments.
Nurix Therapeutics (NRIX)
Jefferies analyst Roger Song maintained a Buy rating on Nurix Therapeutics today and set a price target of $41.00. The company’s shares closed last Friday at $25.05, close to its 52-week high of $26.43.
According to TipRanks.com, Song ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -12.6% and a 39.2% success rate. Song covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Kiniksa Pharmaceuticals, and Zenas BioPharma, Inc.
Currently, the analyst consensus on Nurix Therapeutics is a Strong Buy with an average price target of $30.50, representing a 23.6% upside. In a report issued on October 14, Barclays also maintained a Buy rating on the stock with a $31.00 price target.
See today’s best-performing stocks on TipRanks >>
Ascendis Pharma (ASND)
TD Cowen analyst Yaron Werber assigned a Buy rating to Ascendis Pharma today and set a price target of $160.00. The company’s shares closed last Friday at $129.90.
According to TipRanks.com, Werber is a 5-star analyst with an average return of 14.7% and a 57.7% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Springworks Therapeutics, and Ionis Pharmaceuticals.
Currently, the analyst consensus on Ascendis Pharma is a Strong Buy with an average price target of $196.77.
Lantheus (LNTH)
In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Lantheus, with a price target of $145.00. The company’s shares closed last Friday at $116.69, close to its 52-week high of $126.89.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of 9.3% and a 59.1% success rate. Taylor covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Allurion Technologies.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Lantheus with a $146.63 average price target.
Read More on NRIX: